| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169451A2 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169443A1 REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY p21 |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169351A1 Polypeptides derived from endostatin exhibiting antiangiogenic activity |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169346A1 48 human secreted proteins |
| 01/09/2002 | EP1169342A2 Tuberculosis antigens and methods of use therefor |
| 01/09/2002 | EP1169339A1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169322A1 Pyridoxal analogues for vitamin b-6 disorders |
| 01/09/2002 | EP1169320A1 Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof |
| 01/09/2002 | EP1169318A1 Prodrugs of thrombin inhibitors |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169316A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169312A2 Glucokinase activators |
| 01/09/2002 | EP1169307A1 Pyrimidine compounds with pharmaceutical activity |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169294A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169244A2 Metering valve |
| 01/09/2002 | EP1169082A1 Method of providing cosmetic/medical therapy |
| 01/09/2002 | EP1169069A1 Three-dimensional stromal tissue |
| 01/09/2002 | EP1169065A1 Formulations for detecting asthma |
| 01/09/2002 | EP1169060A1 Sodium channel blocker compositions and the use thereof |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169049A2 Treatment of myeloma bone disease with proteasomal and nf-kappa-b activity inhibitors |
| 01/09/2002 | EP1169045A2 Immunomodulating polymers |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169041A2 Use of carbamic acid derivatives for the treatment of viral infections |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168912A1 Organ arrest, protection and preservation |
| 01/09/2002 | EP0996617B1 2,4-Dithi(oxo)-pyridin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists |
| 01/09/2002 | EP0984699A4 Method of inhibiting immune system destruction of transplanted viable cells |
| 01/09/2002 | EP0789764B1 A novel family of protease inhibitors, and other biologic active substances |
| 01/09/2002 | EP0607439B1 Nitrogenous heterocyclic compound |
| 01/09/2002 | CN1330713A Zinc finger binding domains for GNN |
| 01/09/2002 | CN1330664A Platelet-derived growth factor C, DNA coding therefor and uses thereof |
| 01/09/2002 | CN1330661A Procollagen C-proteinase inhibitors |
| 01/09/2002 | CN1330660A Cycle tetrapeptide compound and their use |
| 01/09/2002 | CN1330658A Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 01/09/2002 | CN1330653A 4,5-pyrazinoxindoles as protein kinase inhibitors |
| 01/09/2002 | CN1330650A Dibenz [a.g] quinolizinium derivatives and salts thereof |
| 01/09/2002 | CN1330648A 4-aryloxindoles as inhibitor of JNK protein kinases |
| 01/09/2002 | CN1330647A 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 |
| 01/09/2002 | CN1330643A IL-5 inhibiting azauracil pyrimidine derivatives |
| 01/09/2002 | CN1330642A N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330636A Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330630A 7-aryl-6(z) heptantriene acid vitamin A amide as apoptosis inducing compounds and their use as anti-cancer agents |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330550A Use of substances with oxytocin activity in order to create cell regeneration |
| 01/09/2002 | CN1330545A Treating for skin disease |
| 01/09/2002 | CN1330542A Method and composition for maintanance and restitution gut integrity |
| 01/09/2002 | CN1330539A Compositions and methods for treatment of anorectal disorders |
| 01/09/2002 | CN1330538A Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 01/09/2002 | CN1330536A Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same |
| 01/09/2002 | CN1330077A Endothelin antegon |
| 01/09/2002 | CN1330076A Endothelin antagon |
| 01/09/2002 | CN1330067A 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their |
| 01/09/2002 | CN1329904A Process for preparing arnebia root medicine with broad-spectrum medical functions |
| 01/09/2002 | CN1329889A Concentrated granular medicine for treating baby cold and preparation process thereof |
| 01/09/2002 | CN1077573C Heterocycles useful as neurokinin antagonists |
| 01/09/2002 | CN1077568C Phenoxyphenyl cyclopentenyl hydroxyureas |
| 01/09/2002 | CN1077434C Chinese medicinal powder for treating toothache and preparation method thereof |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337394 N-acyl-heterocycle-carboxyamides that are n-substituted with amidino-substituted rings; competitive inhibitors of thrombin; anticoagulants |
| 01/08/2002 | US6337350 Inhibitors of formation of advanced glycation endproducts (AGEs) |
| 01/08/2002 | US6337349 Stable and nonhygroscopic salts to form tablets, capsules, powders, etc. suitable for dietary/nutritional humans supplements and a feed supplement for veterinary medicine; high-energy metabolism; cardiovascular systems |
| 01/08/2002 | US6337342 Bis-aryl or heteroaryl indoles |
| 01/08/2002 | US6337335 Enzyme inhibitors for autoimmune diseases, transplant rejection, grant versus host disease, hyperproliferative disorders and diseases in which cells receive pro-inflammatory signals. |
| 01/08/2002 | US6337331 Triazolo-pyrimidine as ligands for GABA receptors |
| 01/08/2002 | US6337328 Bupropion metabolites and methods of use |
| 01/08/2002 | US6337316 Pharmaceutical compositions thereof, and methods of using same |
| 01/08/2002 | US6337075 Methods for treating diabetes |
| 01/08/2002 | CA2193087C Topical compositions comprising n-acetyl-l-cysteine |
| 01/08/2002 | CA2143263C Orally administrable raloxifene formulations |
| 01/08/2002 | CA2038744C Pharmaceutical composition containing slightly water-soluble drug |
| 01/03/2002 | WO2002000906A2 Replication deficient adenoviral tnf vector |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000876A1 Truncated egf receptor |
| 01/03/2002 | WO2002000871A2 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000840A2 Human lyases |
| 01/03/2002 | WO2002000839A2 Statement as to federally sponsored research |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000724A2 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | WO2002000711A2 Ev-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000684A2 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 01/03/2002 | WO2002000679A2 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group |